Argus raised the firm’s price target on Thermo Fisher (TMO) to $610 from $580 and keeps a Buy rating on the shares after its “strong” Q3 earnings beat. The company is shrewdly deploying capital for M&A, facility expansions, and new product offerings such as AI tools, while the results also show that the end market conditions are improving, the analyst tells investors in a research note. Thermo Fisher’s recently announced collaboration with OpenAI presents another growth opportunity, the firm added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Thermo Fisher Announces Acquisition of Clario Holdings
- Thermo Fisher to acquire Clario Holdings for $8.875B in cash at close
- M&A News: Thermo Fisher (TMO) Nears $10B Clario Takeover to Strengthen Clinical Trial Tech
- Thermo Fisher price target raised to $656 from $560 at Morgan Stanley
- Thermo Fisher’s Positive Q3 Results and Optimistic Growth Outlook Justify Buy Rating and Increased Price Target